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Introduction
The pathogenesis and clinical phenotype of oral mucositis 
caused by high- dose chemotherapy or radiotherapy are 
well described in the literature [1–8]. In contrast, a unique 
manifestation of oral mucosal injury has been documented 
within the past 5 years in association with mammalian 
target of rapamycin (mTOR) inhibitors [8–10]. This latter 
toxicity has now emerged as one of the most common 
adverse events associated with targeted cancer therapies 
[11–16], including in women being treated for invasive 
breast cancer [17, 18].
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Abstract
In recent years oral mucosal injury has been increasingly recognized as an 
important toxicity associated with mammalian target of rapamycin (mTOR) 
inhibitors, including in patients with breast cancer who are receiving everolimus. 
This review addresses the state- of- the- science regarding mTOR inhibitor- 
associated stomatitis (mIAS), and delineates its clinical characteristics and man-
agement. Given the clinically impactful pain associated with mIAS, this review 
also specifically highlights new research focusing on the study of the molecular 
basis of pain. The incidence of mIAS varies widely (2–78%). As reported across 
multiple mTOR inhibitor clinical trials, grade 3/4 toxicity occurs in up to 9% 
of patients. Managing mTOR- associated oral lesions with topical oral, intrale-
sional, and/or systemic steroids can be beneficial, in contrast to the lack of 
evidence supporting steroid treatment of oral mucositis caused by high- dose 
chemotherapy or radiation. However, steroid management is not uniformly ef-
ficacious in all patients receiving mTOR inhibitors. Furthermore, technology 
does not presently exist to permit clinicians to predict a priori which of their 
patients will develop these lesions. There thus remains a strategic need to define 
the pathobiology of mIAS, the molecular basis of pain, and risk prediction 
relative to development of the clinical lesion. This knowledge could lead to 
novel future interventions designed to more effectively prevent mIAS and  improve 
pain management if clinically significant mIAS lesions develop.
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The clinical trajectory and response to therapy of these 
two types of oral mucosal injury are distinctly different. 
It is thus biologically plausible to theorize that there are 
key pathobiological differences between the two conditions 
as well; in this context, terminology that appropriately 
differenciates between the two conditions becomes impor-
tant. To distinguish between the two types of lesions at 
the research and clinical levels [7, 19], mTORI-associated 
stomatitis (mIAS) [9, 10] has become the preferred descrip-
tor of the mTOR inhibitor−associated toxicity.
This review summarizes the state- of- the- science regarding 
the pathobiology, clinical characteristics, and management of 
mIAS, and delineates new research directions with an emphasis 
on the pathogenesis of oral mucosal pain. Additionally, this 
article is designed to provide the clinician with current man-
agement approaches and encourage novel basic, translational, 
and clinical studies that could enhance the future care of 
patients with cancer who will receive mTOR inhibitors.
Phenotype, Incidence, and 
Pathobiology of mTOR Inhibitor–
Associated Stomatitis
mIAS typically presents as multiple or singular round to 
ovoid ulcerations with regular borders [7]. The lesions 
are commonly less than 0.5 cm in diameter in size and 
nearly exclusively involve the nonkeratinized oral mucosa 
(i.e., tongue, floor of the mouth, and labial or buccal 
mucosa) [7] (Fig. 1). The occurrence of mIAS appears 
to be dose- related; the pain and resultant limitations in 
oral function can be greater than what might be antici-
pated by the clinician based on the relatively small size 
of the lesions as compared to other types of oral mucosal 
injury [9]. The intensity of a patient’s subjective oral pain 
experience with mIAS lesions is thus not always com-
mensurate with the degree of oral erythema or ulceration 
observed clinically.
Incidence of the oral lesions can be high. For example, 
Martins and colleagues analyzed multiple clinical studies 
of mIAS in 2,822 patients with cancer who were treated 
with temsirolimus, everolimus, or ridaforolimus and 
reported an all- grade mIAS incidence of 52.9%, with 
incidence varying among the agents [9]. Based on evalu-
ation of clinical trials, the incidence of all grades of sto-
matitis caused by mTOR inhibitors can vary considerably, 
ranging from 2% to 78% [9, 20–22] (Table 1).
Despite the advances relative to the clinical assess-
ment and treatment of these lesions, delineation of 
the pathobiology of mIAS remains limited. This con-
trasts with oral mucositis caused by conventional 
Figure 1. Distinguishing oral mucosal injury of mammalian target of rapamycin inhibitor–associated stomatitis (mIAS) from chemotherapy- associated 
oral mucositis, herpetiform stomatitis, and recurrent aphthous ulceration. (A) Conventional chemotherapy- induced oral mucositis in a 62- year- old 
male with multiple myeloma receiving high- dose melphalan during peripheral blood stem cell transplant. (B) mIAS in a 58- year- old female with breast 
cancer at ~22 days since receiving everolimus 10 mg/day (note the clinical similarity to solitary herpetiform and recurrent aphthous ulcers with lack of 
intense inflammatory halo). (C) Herpetiform stomatitis in a 34- year- old female in otherwise excellent health. (D) Recurrent aphthous ulceration in an 
18- year- old male without cancer, with a spontaneous recurrent oral lesion history of approximately three events per year.
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high- dose chemotherapy and for which the pathobiology 
has been studied for the past two decades (Fig. 2) [2, 
6, 23–27]. Insights into the mechanism of action of 
mTOR inhibitors and naturally occurring oral mucosal 
lesions such as recurrent aphthous ulceration may thus 
be valuable in informing future research directions 
involving mIAS.
It is, for example, well established that the mTOR 
signaling pathway physiologically functions as a central 
modulator of extracellular and intracellular signaling of 
mediators and growth factors that in turn regulate molecu-
lar and cellular events involved in growth, translation, 
and metabolism [28]. In comparison, mTOR inhibition 
can cause dysregulation of these molecular and cellular 
events and include a decrease in expression of CD4+ 
CD25+ regulatory T cells and T- cell (predominately CD8 
cytotoxic T cells) infiltration and upregulation of heat 
shock protein 27 and interleukin- 10 [7, 29].
Until further research determines the molecular basis 
of mIAS, it is thus biologically plausible to conceptualize 
a pathobiologic model of mIAS in relation to the mul-
tifactorial mechanistic basis and clinical profile of recur-
rent aphthous ulceration as defined in the literature 
(Table 2) [7, 9, 10, 30–37]. Possible risk factors for 
recurrent aphthous ulceration have classically included 
anxiety and stress, hormonal alteration, and/or nutritional 
deficiency.
However, the collective supporting evidence associated 
with these possible risks remains weak [38]. Two recently 
delineated recurrent aphthous ulceration–related factors 
described below in the “Oral microbiota” and “Genetic 
governance” sections, provide important context for future 
studies of mIAS.
Oral microbiota
Study of the oral microbiota of patients with and without 
recurrent aphthous ulceration has suggested a relationship 
between a disturbance in the normal oral mucosal flora 
and the development of recurrent aphthous ulceration 
[30]. The study of microbiota of the buccal mucosa, rather 
than of the ulcer per se, was a unique design considera-
tion of this analysis. The authors’ rationale for this approach 
was based on the relevance of studying preconditions for 
recurrent aphthous ulceration development, rather than 
examining the effect of inflammation directly associated 
with currently existent ulcerative lesions. The microbiota 
of noninflamed buccal mucosa differed between patients 
and controls. The differences were most evident when 
patients exhibited recurrent aphthous ulceration present 
during the sampling. These findings raise the question of 
whether active recurrent aphthous ulceration lesions could 
alter the microbiota, or whether changes in the normal 
oral microbiota could induce development of active recur-
rent aphthous ulceration. Of note is that abundant 
Bacteroidales species at the time of acute recurrent aphthous 
ulceration may be important in the pathogenesis of this 
chronic condition [31]. These recent findings that deline-
ate a potential association between the oral microbiome 
and the development of recurrent aphthous ulceration 
provide an important basis for the continued study of 
recurrent aphthous ulceration and mIAS.
Genetic governance
Multiple studies strongly support a genetic basis for recur-
rent aphthous ulceration. It has been suggested by Slebioda 
and colleagues that inheritance of specific gene polymorphism 
coding for proinflammatory cytokine production may be 
an important contributor to the development of recurrent 
aphthous ulceration [35]. These authors also identified a 
correlation between the serotonin transcriptase encoding 
gene polymorphisms and recurrent aphthous ulceration, 
implicating the potential role of stress and psychogenic 
stimuli in ulcer development [35]. Karasneh and colleagues 
recently demonstrated the likely relationship between toll- 
like receptor 4 rs10759931 polymorphism and recurrent 
aphthous ulceration [36]. They note that future studies 
would be valuable relative to potentially targeting the toll- 
like receptor as a treatment strategy for the lesion [36].
The collective evidence involving the mechanisms of mTOR 
inhibitors and the lessons learned at the clinical and research 
levels for recurrent aphthous ulceration may provide impor-
tant context for new research directed to mIAS pathobiology. 
This new knowledge could over time also lead to an enhanced 
ability of the clinician to predict risk for development of 
mIAS and predict the response to therapeutic intervention 
on an individual patient- by- patient approach.
Table 1. Prevalence of oral mucosal lesions associated with mammalian 
target of rapamycin inhibitors [9, 20–22].
mTOR Inhibitor
Oral mucosal lesion prevalence
All grade Grade 3/4
Everolimus [20] 44–78%a 4–9%a
Temsirolimus [21] 41%b 3%b
Ridaforolimus [9] 54.6%c 8.2%c
Sirolimus [22] 2–10%d 0–2%
mTOR, mammalian target of rapamycin.
aClinical trial experience across all oncology indications; includes mouth 
ulcers, stomatitis, and oral mucositis.
bCategorized with the preferred term mucositis and includes aphthous 
stomatitis, glossitis, mouth ulceration, mucositis, and stomatitis.
cData based on five clinical studies involving 194 patients receiving rida-
forolimus in an oncology setting.
dData based on a phase I dose- escalation study of daily oral sirolimus 
with weekly intravenous vinblastine in pediatric patients with advanced 
solid tumors.
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Figure 2. Integration of molecular pain modeling with current pathobiology for oral mucosal injury associated with cancer treatment. The five stages 
of inflammation in oral mucositis pathogenesis as adapted from the model originally created by Sonis [62]. The insert illustrates the integration of the 
molecular neuropathology of pain into this conceptual framework, with identification of mediators, receptors, and specific nociceptor fiber types 
within the trigeminal system that likely convey nociception in oral mucositis [40]. Transient receptor potential (TRP) receptors associated with 
mechanical hyperalgesia include the TRPV1 proton receptor, the TRPA1 cold and chemical irritant receptor, the TRPM8 menthol receptor, and the 
TRPV4 osmolarity receptor. Epithelial cells within the oral mucositis microenvironment secrete interleukin (IL)- 1, IL- 6, tumor necrosis factor (TNF)- α, 
and nerve growth factor (NGF), triggering an inflammatory cascade. TNF- α activates TNFR2, producing a nociceptive response. NGF binds to either 
the low- affinity p75 receptor or the high- affinity TrkA receptor on peptidergic neurons, in turn modulating neurogenic inflammation. Both C fibers 
and A- δ fibers secrete substance P (SP) and calcitonin gene- related peptide (CGRP) in the periphery, and SP, CGRP, and glutamate in the nucleus 
caudalis, to mediate nociception. Secretion of endothelin- 1 (ET- 1) within the oral mucositis microenvironment is hypothesized; ET- 1 production is 
induced by the transcription factor NF- κB, which is upregulated in oral mucositis. TNFR2 and TRPV4 have not been localized to specific fiber types, 
and are shown here on multiple fiber types. Adapted with permission from Sonis [62]. Molecular pain component of figure adapted with permission 
from Viet et al. [40]. © International & American Associations for Dental Research. Reprinted by Permission of SAGE Publications.
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Molecular Basis of Oral Mucosal 
Injury
As noted previously, clinically significant oral pain is a 
prominent feature of oral mucosal injury caused by con-
ventional and targeted cancer therapies, despite the likely 
differences in the pathobiology of both conditions. Oral 
pain can profoundly impact the patient’s oral function 
and overall quality of life (QOL) [39]. In addition, the 
oral pain can limit administration of chemotherapy and 
mTOR inhibitors, resulting in delivery of suboptimal cancer 
treatment dosing [3]. Unfortunately, treatments with nono-
pioid analgesics may not adequately control oral pain in 
some patients [39]. These patients may thus require high- 
dose opioid therapy, with its attendant toxicities, for control 
of oral pain.
Despite the clinical importance of pain from cancer 
therapy- induced oral mucosal injury, its etiology and 
pathobiology have not been well  defined in the setting 
of mTOR inhibitors because of difficulty in generating 
preclinical models that replicate oral ulceration and pain 
in patients receiving these targeted therapeutics. Drawing 
on related research may thus provide important insights 
for future research and management regarding the mIAS 
pain component.
The model delineated by Viet and colleagues is thus 
highly relevant in this regard [40]. Integration of this 
pain model into the current oral mucositis pathobiologic 
paradigm is depicted in Figure 2. The potential transla-
tion of this pain modeling with oral mucositis caused 
by chemotherapy and/or radiation to mIAS may represent 
a new frontier in the research of pain associated with 
mIAS. In the Viet model, nociceptive afferents for pain 
are primarily conveyed by the A- δ and C fibers in the 
oral cavity by interaction with varying receptors, includ-
ing the transient receptor potential (TRP) family of 
sensory ion- channel proteins, endothelin- 1 (ET- 1), tumor 
necrosis factor alpha (TNF- α), and nerve growth factor 
(NGF) receptors [40]. TRP receptors are expressed on 
trigeminal ganglion neurons involved in thermal and 
mechanical nociception in the orofacial region [40]. 
Activation of TRP leads to the release of ET- 1, which 
is a vasoactive and nociceptive peptide that mediates 
nociception in all trigeminal branches. ET- 1 is implicated 
in the molecular pathogenesis of oral mucositis though 
a putative link with the NF- ĸB transcription factor that 
is activated in response to oxidative stress [40]. 
Neurotrophic factors such as NGF are secreted by neu-
rons, inflammatory cells, and cancer cells, in turn, medi-
ating pain by the binding of these factors to receptors 
on peptidergic C fibers [40]. Peripheral release from 
peptidergic C fibers produces the neurogenic inflamma-
tion that characterizes the complex pain response involved 
with oral mucositis [40, 41]. Peripheral afferent nocicep-
tors are also sensitized by proinflammatory cytokines, 
including TNF- α, IL- 2, IL- 6, and IL- 1β, generated at 
the site of oral mucosal injury [40, 41]. The effect of 
anti- inflammatory cytokines in reducing oral mucositis 
has been explored. However, although multiple preclinical 
studies suggested potential benefit, these benefits have 
not been verified in clinical studies [42].
Further research relative to oral pain associated with 
oral mucositis caused by chemotherapy and/or head and 
neck radiation as well as mIAS could thus lead to novel 
approaches for risk prediction of pain and responses to 
pain management. These strategic advances could sub-
stantively contribute to maintaining optimal cancer treat-
ment protocol for each individual and enhancing his/
her QOL during treatment.
Table 2. Comparison of recurrent aphthous ulceration with mammalian 
target of rapamycin inhibitor– associated stomatitis [7, 9, 10, 30–37].
Epidemiology and pathobiology: current gaps
Domain Recurrent aphthous ulcers mIAS
Recently identified 
potential risk 
factors
Oral microbiota
Genetic governance
Unknown
Unknown
Molecular basis Immune dysregulation, 
including:  
Decreased expression of 
CD4 + CD25+ regulatory 
T cells  
Cytotoxic T- cell infiltration 
Upregulation of proinflamma-
tory cytokines (e.g., TNF, IL- 2, 
IL- 6)
Unknown 
 
Unknown 
 
 
Unknown
Unknown
Clinical characteristics: current similarities
Domain Recurrent aphthous ulcers mIAS
Duration Typically 7–10 days <1 week to 
≥2 weeks
Clinical 
phenotype
Shallow ulcerations, with 
intense erythematous 
margins 
Involves nonkeratinized oral 
mucosa pain
Comparable to 
recurrent 
aphthous ulcers
Response to 
therapeutics
Responsive to locally or 
systemically administered 
steroids
Comparable to 
recurrent 
aphthous ulcers
Pain 
management
Steroid management may be 
supplemented with topical 
administration of local 
anesthetics, often delivered 
via a mucoadherent vehicle
Comparable to 
recurrent 
aphthous ulcers
IL2, interleukin 2; IL6, interleukin 6; TNF, tumor necrosis factor.
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Clinical Assessment and Grading of 
mTOR Inhibitor– Associated Stomatitis
Although mIAS is recognized as a distinct clinical entity, 
clinical trials assessing mIAS have often utilized a variety 
of descriptive terms to identify this condition, including 
oral mucositis and stomatitis. The differential diagnosis of 
mIAS includes recurrent aphthous stomatitis, which may 
also occur during treatment but is unrelated to mTOR 
inhibition. Given the clinical similarities between mIAS and 
recurrent aphthous stomatitis [9, 10], the inability to dif-
ferentiate between these two conditions is likely to result 
in overestimation of the true incidence of mIAS in these 
patients. Additionally, the incidence and natural history of 
mIAS have been reported by utilizing grading scales devel-
oped to assess conventional oral mucositis (e.g., World 
Health Organization, Oral Mucositis Assessment Scale, 
National Cancer Institute Common Terminology Criteria 
for Adverse Events [NCI CTCAE]) [9]. However, applying 
criteria for oral mucositis caused by conventional chemo-
therapy and radiation therapy can lead to imprecise reporting 
of mIAS incidence, progression, and severity [9]. For exam-
ple, version 3.0 of the NCI CTCAE includes scales for 
subjective oral mucositis measures, including pain and ability 
to eat, and objective measures, including extent of erythema 
and ulcerations [9]. Because most ulcers associated with 
mIAS are <0.5 cm in diameter, the majority of lesions 
would not be classified as grade 2 (patchy ulceration) by 
NCI CTCAE version 3.0. This approach would then poten-
tially result in underreporting of mIAS severity [9]. Version 
4.0, in comparison, assesses symptoms and the functional 
effects of oral mucositis, focuses on the associated pain, 
and is more appropriately suited to grading mIAS [43].
Given these gaps in assessment technology, a scale spe-
cifically developed for evaluation and grading of mIAS 
in oncology patients was proposed by Boers- Doets and 
Lalla [44]. This innovative instrument includes measure-
ments of subjective pain and objective measurements of 
lesion duration [44]. This tool could lead to enhanced 
understanding of the functional and QOL impact of mIAS 
based on validation in future, larger studies. In this con-
text, consideration of additional parameters, including the 
patient’s ulcer frequency, size, and number and degree 
of difficulty while eating, could be valuable. Because the 
impact of pain on oral function is a consistent feature 
in mIAS, we advocate inclusion of a scale to evaluate a 
patient’s nutritional intake as well.
Impact of mTOR inhibitor– Associated 
Stomatitis on Therapy Administration
The effect of dose interruption or reduction of mTOR 
inhibitors in managing mIAS has been studied in several 
patient cohorts [9, 45]. Martins and colleagues reported 
that dose reduction occurred in 19.2% of mTOR inhibitor- 
treated patients, most frequently for thrombocytopenia 
(35.2%) and oral mucositis (27.3%) [9]. In the BOLERO- 2 
study, 24% of patients treated with everolimus plus 
exemestane required dose interruptions or adjustments 
for any- grade mIAS [45]. Most occurrences of mIAS 
were successfully managed with palliative interventions, 
including topical and systemic pain control; however, 
subsequent dose modifications were also documented 
[45]. Despite adequate management of mIAS, it was the 
second most common toxicity that led to discontinua-
tion of treatment (3% for everolimus plus exemestane 
vs. <1% for placebo plus exemestane) [45]. However, 
in most patients with grade 3 mIAS in the everolimus 
plus exemestane arm, stomatitis resolved to grade ≤1 at 
3.1 weeks and resolved completely in 82% of patients 
at 7.4 weeks [45].
Preventing and Treating mTOR 
Inhibitor–Associated Stomatitis
Patient awareness, diligent monitoring, and timely man-
agement of mIAS are necessary to ensure that patients 
remain on mTOR inhibitor treatment [17, 18]. As noted 
in Table 3, prophylactic measures to prevent mIAS have 
been proposed by expert panel groups [17, 46, 47]. In 
comparison, study of the use of topical or systemic cor-
ticosteroids for mIAS treatment suggests their possible 
efficacy [14, 48, 49]. A single- center retrospective analysis 
of patients with cancer treated with the mTOR inhibitors 
everolimus or ridaforolimus determined that 87% of 
patients reported clinical improvement of mIAS (87%) 
after treatment with topical or systemic corticosteroids 
[48]. This outcome is consistent with the report that topi-
cal clobetasol treatment reduced aphthous ulceration in 
renal transplant patients receiving sirolimus [50]. In addi-
tion, the steroid mouth rinses and “magic” mouthwashes, 
often used for the palliative management of chemotherapy- 
induced stomatitis, have been suggested for the prevention 
and treatment of mIAS [17, 46]. A case report of a patient 
with mIAS for whom treatment included topical dexa-
methasone, intralesional injections of the corticosteroid 
triamcinolone, and magic mouthwash oral rinse demon-
strated significant improvement in the signs and symptoms 
of mIAS lesions [47]. However, the collective studies report 
an overall lack of effectiveness for managing mIAS with 
the prophylactic use of other oral rinses, such as antiseptic- 
based [51] or sodium bicarbonate- based mouthwashes 
[52].
The mIAS prevention and treatment strategies used in 
the BOLERO- 2 study and dose- modification instructions 
highlighted in the everolimus package insert are also 
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Table 3. Suggested strategies to prevent or manage mammalian target of rapamycin inhibitor– associated stomatitis [17, 20, 46, 47].
Prompt reporting
• Educate patient on common signs and symptoms
• Educate patient to contact caregiver at first sign of mouth discomfort
• Educate patient to contact caregiver if lesions occur that interfere with eating and/or drinking
Basic oral care and oral hygiene
• Instruct patient to:
o Perform consistent, regular, and thorough brushing with a soft toothbrush; floss after each meal
o Frequently rinse with bland rinses such as sterile water, normal saline, or sodium bicarbonate
o Avoid alcohol-containing rinses and toothpastes with sodium lauryl sulfate
o Avoid alcohol- or peroxidase-containing mouthwash products
o Avoid acidic, spicy, hard, or crunchy foods that may injure the oral epithelium, and consume foods that are tepid rather than hot
• Consider use of oral moisturizers
• Emphasize need for regular dental examinations
• Treat anticipated infections (e.g., periodontal disease)
Assessment of other possible oral morbidities
• Evaluate for herpetic, bacterial, and fungal infections
• Administer antimicrobials as appropriate
Pharmacologic treatment
Ingredients Schedule
Topical local anestheticsa Local anesthetics: lidocaine, benzocaine, butyl 
aminobenzoate, tetracaine hydrochloride
5 mL swish and expectorate as needed for pain, up to five 
times a day
Topical steroids Dexamethasone, 0.5 mg/5 mL 5−10 mL swish and hold for 4–6 min, depending on 
patient tolerance, and expectorate; repeat three to four 
times daily
Clobetasol gel, 0.05% Apply to oral ulcers on a gauze pad; hold in place 5−10 min 
twice daily
Prednisolone oral solution 15 mg/5 mL 5 mL swish and hold for 4–6 min, depending on patient 
tolerance, and expectorate; repeat three to four times  
daily
Triamcinolone, 0.1% cream Apply a thin film over the oral ulcer three times daily
Compounded steroid oral 
rinse
320 mL of diphenhydramine oral solution 
2 g of tetracycline powder 80 mg of hydrocorti-
sone (four 20- mg tablets crushed) 40 mL of 
nystatin suspension; dilute with water to 480 mL
10 mL solution four times daily (swish for 4–6 min, depending 
on patient tolerance, and expectorate)
Systemic steroids Prednisone 5 mg 5 mg, one to two times daily (for severe resistant mIAS)
Dose adjustment of mTOR inhibitor (e.g., everolimus)b
Grade Symptoms Everolimus dose modification
1 Minimal (normal diet) No dose adjustment necessary
2 Symptomatic, but can eat and swallow modified 
diet
Temporary dose interruption until recovery to grade ≤1; 
reinitiate everolimus at the same dose 
If stomatitis reoccurs at grade 2, interrupt dose until 
recovery to grade ≤1; reinitiate everolimus at a lower  
dose
3 Symptomatic and unable to adequately eat or 
hydrate orally
Temporary dose interruption until recovery to grade ≤1; 
reinitiate everolimus at a lower dose
4 Severe (symptoms are life threatening) Discontinue everolimus and treat with medical therapy as 
indicated
mIAS, mTOR inhibitor–associated stomatitis; mTOR, mammalian target of rapamycin.
aSystemic pain medication may be needed with severe pain.
bAs described in the package insert for everolimus [20].
1904 © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
D. E. Peterson et al.Oral Mucosal Injury Caused by mTOR
outlined in Table 3 [20]. Current management guidelines 
of oral mucosal injury focus on oral mucositis associated 
with chemotherapy or radiotherapy [8, 53–55]. New guide-
lines specifically developed for the prevention and treat-
ment of mIAS are needed.
Future Directions
The current state- of- the- science delineates at least three 
key areas for future research, as described in the sections 
below.
Terminology
As mentioned, mTOR inhibitor– associated stomatitis [9, 
10] has become the preferred descriptor over oral mucositis 
in order to differentiate the oral mucosal lesions associ-
ated with targeted therapies from the oral mucositis 
caused by conventional cancer therapy [7, 19]. This 
revised terminology represents a valuable contribution 
to the literature in that it differentiates oral mucosal 
injury caused by conventional cancer treatment from 
oral mucosal injury caused by targeted cancer therapy. 
This terminology may further evolve in the future, when 
the pathobiology and clinical presentation of oral mucosal 
lesions caused by different types of molecularly targeted 
therapies become further defined. This evolution may 
result in elimination of the word “stomatitis,” which is 
broadly descriptive relative to inflammatory lesions of 
the oral cavity.
Factors related to clinical risk prediction
Continued study of treatment- related risk factors (e.g., 
drug, dosing schedule, administration route, concomi-
tant therapies) and patient- related risk factors (e.g., age, 
gender, body mass index, oral [including periodontal] 
health, hepatic or renal function, drug metabolism 
pharmacogenetics) could provide important insights into 
novel mechanistic pathways and associated targeted 
clinical management for mIAS. As previously noted, 
studying putative etiologies of recurrent aphthous ulcera-
tion, such as oral microbiota and genetic governance 
may be useful in assessing the risk for development of 
mIAS.
Recent advances in the computational molecular mod-
eling of oral mucositis risk in the context of conventional 
high- dose cancer therapies may provide novel insights into 
clinical risk prediction for mIAS as well [56–58]. For 
example, single- nucleotide polymorphisms (SNPs) derived 
from salivary DNA in patients undergoing hematopoietic 
stem cell transplants were assessed as predictors for risk 
of severe oral mucositis [59]. An 82- SNP Bayesian network 
related to risk was identified that had >99% cross- validation 
accuracy and a predictive accuracy of 81% [59]. It is 
interesting to consider whether such pharmacogenomic 
studies could also identify genetic predictors of mIAS risk. 
Although aphthous- like ulcerations primarily affect non-
keratinized oral mucosal tissues [7], future studies into 
the pathobiology and genetic factors involved in mIAS 
should also assess nonoral mucosal tissue and other nonoral 
tissues, such as skin and nails, for potential associations.
Prevention and treatment
Prevention
The everolimus package insert currently recommends that 
patients receiving everolimus for treatment of subependy-
mal giant cell astrocytoma undergo measurement of an 
everolimus trough level 2 weeks after beginning therapy 
[20]. In these patients, the dose is adjusted to attain trough 
concentrations of 5–15 ng/mL [20], an amount that may 
help prevent mIAS. However, it is currently unknown 
whether targeting the same everolimus trough concentra-
tion in patients with metastatic breast or renal cancer 
would reduce the incidence of mIAS.
Treatment
Ongoing studies of steroid mouth rinses are promising 
in that their results may contribute to new strategies for 
the reduction in clinical expression of mIAS. To this end, 
two trials (NCT02069093 and NCT02229136) in patients 
with metastatic breast cancer utilizing dexamethasone or 
prednisolone mouth rinses or compounded oral steroid 
rinse to reduce the incidence of or prevent mIAS are 
currently ongoing [60, 61] (Table 2). These trials are 
evaluating whether steroid mouth rinses can prevent and/
or treat early mIAS, thereby decreasing the incidence of 
this toxicity and increasing the therapeutic index of mTOR 
inhibitor therapy.
Such studies of oral topical steroids are important 
because pharmacokinetic interactions between everolimus 
and a systemic steroid such as dexamethasone as medi-
ated through the CYP3A4 metabolic pathway could lead 
to a reduction in the efficacy of everolimus. Topical oral 
dosing of the steroid minimizes this risk. However, pro-
longed corticosteroid exposure in the setting of chronic 
or severe mIAS with large areas of ulceration may result 
in adverse clinical sequelae secondary to elevated plasma 
steroid levels.
Conclusions
mIAS occurs early during mTOR inhibitor treatment, is 
associated with significant morbidity, and can impair 
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delivery of therapy. This can include women with invasive 
breast cancer who are receiving an mTOR inhibitor as a 
component of their treatment regimen. Prophylactic strate-
gies, including oral hygiene and avoiding injury to the 
epithelium of the oral cavity, are recommended. The 
promising prevention and treatment strategies that are 
being evaluated in clinical trials are based, in part, on 
the observation of the clinical similarity and response to 
therapy of mIAS to recurrent aphthous ulceration. 
However, mIAS continues to be a clinically consequential 
toxicity in many patients. New research directed to the 
oral pain associated with mIAS could strategically enhance 
the clinical management of these patients, including pre-
serving optimal treatment regimens while enhancing the 
patient’s QOL.
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